(Q45218155)

10 December 2017

Efficacy and safety comparative evaluation of orlistat and sibutramine treatment in hypertensive obese patients (English)

1 reference

10 December 2017

0 references

1 reference

1

1 reference

10 December 2017

2

1 reference

10 December 2017

Murdolo G

3

1 reference

10 December 2017

Piccinni MN

4

1 reference

10 December 2017

Fogari E

5

1 reference

10 December 2017

Bertone G

6

1 reference

10 December 2017

Ciccarelli L

7

1 reference

10 December 2017

Fogari R

8

1 reference

10 December 2017

1 January 2005

1 reference

Diabetes, Obesity and Metabolism

10 December 2017

1 reference

10 December 2017

7

1 reference

10 December 2017

47-55

1 reference

10 December 2017

1

1 reference

Pharmacotherapy of obesity.

10 December 2017

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2004.00372.X

Pharmacokinetic evaluation of the possible interaction between selected concomitant medications and orlistat at steady state in healthy subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2004.00372.X

Orlistat enhances warfarin effect

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2004.00372.X

Weight management and current options in pharmacotherapy: orlistat and sibutramine

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2004.00372.X

21 January 2018

Cardiovascular disease.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2004.00372.X

Recent developments in the treatment of obesity-related hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2004.00372.X

Weight control and risk factor reduction in obese subjects treated for 2 years with orlistat: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2004.00372.X

Evaluation of the safety and efficacy of sibutramine, orlistat and metformin in the treatment of obesity

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2004.00372.X

Randomized, double-blind, placebo-controlled comparison of the action of orlistat, fluvastatin, or both an anthropometric measurements, blood pressure, and lipid profile in obese patients with hypercholesterolemia prescribed a standardized diet

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2004.00372.X

Effect of orlistat-induced weight loss on blood pressure and heart rate in obese patients with hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2004.00372.X

Orlistat improves blood pressure control in obese subjects with treated but inadequately controlled hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2004.00372.X

Paradoxical effect of sibutramine on autonomic cardiovascular regulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2004.00372.X

Efficacy and safety of sibutramine for weight loss in obese patients with hypertension well controlled by beta-adrenergic blocking agents: a placebo-controlled, double-blind, randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2004.00372.X

Sibutramine is safe and effective for weight loss in obese patients whose hypertension is well controlled with angiotensin-converting enzyme inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2004.00372.X

Treatment of obesity: an update on anti-obesity medications

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2004.00372.X

10.1111/J.1463-1326.2004.00372.X

21 January 2018

Identifiers

DOI

1 reference

10 December 2017

1 reference